Survival Benefit of Synchronous Lenvatinib Combined PD-1 Inhibitors for Advanced Hepatocellular Carcinoma Beyond Oligometastasis
Survival Benefit of Lenvatinib Plus PD-1 Inhibitor With or Without HAIC in Advanced Hepatocellular Carcinoma Beyond Oligometastasis: A Multicenter Cohort Study
Treatment Strategies and Long-Term Outcomes for Patients With Oligometastasis in Esophageal Squamous Cell Carcinoma After Radical Esophagectomy